Form 8-K C4 Therapeutics, Inc. For: Feb 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Credit Suisse Upgrades C4 Therapeutics (CCCC) to Neutral, 'Improved Outlook w/ Multiple Shots on Goal Post 4Q22 EPS'
February 24, 2023 1:24 PM ESTCredit Suisse analyst Richard Law upgraded C4 Therapeutics (NASDAQ: CCCC) from Underperform to Neutral with a price target of $10.00 (from $12.00).
The analyst comments "CCCC reported 4Q22 financial results on Thursday morning with GAAP EPS of -$0.65. Total collaboration revenues... More
